Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib for 35 days followed by drug withdrawal

ABSTRACT: To investigate whether changes to chromatin accessibility associated with resistance to lapatinib are a stable or a reversible state, we treated OE19 cells with 500 nM lapatinib for 35 days and then withdrew lapatinib for 1, 2, 3 and 14 days. Control cells treated with DMSO for 1 day and 'resistant' cells treated with 500 nM lapatinib for 35 days were also sequenced.

INSTRUMENT(S): Illumina HiSeq 4000

ORGANISM(S): Homo sapiens

SUBMITTER: Samuel Ogden

PROVIDER: E-MTAB-10314 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

ATAC-seq of human oesophageal adenocarcinoma WTSI-OESO_009 (CAM408) organoid treated with lapatinib

Project description:To investigate initial changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on WTSI-OESO_009 cells treated with 1000 nM lapatinib for 24 hours and vehicle control (DMSO) for 24 hours.

2022-09-26 | E-MTAB-10306 | biostudies-arrayexpress

ATAC-seq of human oesophageal adenocarcinoma KYAE1 cell line treated with lapatinib

Project description:To investigate initial changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on KYAE1 cells treated with 500 nM lapatinib for 24 hours and vehicle control (DMSO) for 24 hours.

2022-09-26 | E-MTAB-10310 | biostudies-arrayexpress

ATAC-seq of human gastric adenocarcinoma NCI-N87 cell line treated with lapatinib

Project description:To investigate initial changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on NCI-N87 cells treated with 250nM lapatinib for 24 hours and vehicle control (DMSO) for 24 hours.

2022-09-26 | E-MTAB-10313 | biostudies-arrayexpress

ATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib

Project description:To investigate changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.

2022-09-26 | E-MTAB-10302 | biostudies-arrayexpress

ATAC-seq of human oesophageal adenocarcinoma ESO26 cell line treated with lapatinib

Project description:To investigate initial changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on ESO26 cells treated with 500 nM lapatinib plus 1000 nM MK-2206 (an AKT inhibitor) for 24 hours and vehicle control (DMSO) for 24 hours.

2022-09-26 | E-MTAB-10307 | biostudies-arrayexpress

ATAC-seq of oesophageal adenocarcinoma patient samples

Project description:Open chromatin profiling (ATAC-seq) of human oesophageal adenocarcinoma patient samples.

2020-09-30 | E-MTAB-8447 | biostudies-arrayexpress

ATAC-seq of Fh1-WT, Fh1-KO and Fh1-rec cells

Project description:To identify accessible regions of the genome, we performed ATAC-seq.

2022-09-01 | E-MTAB-11789 | biostudies-arrayexpress

ATAC-seq of OE19 cells treated with either siNT or siERBB2

Project description:To investigate the effect on chromatin accessibility with reduced ERBB2 signalling in oesophageal adenocarcinoma, we performed ATAC-seq in OE19 cells treated with either siNT or siERBB2.

2020-09-30 | E-MTAB-8576 | biostudies-arrayexpress

ATAC-seq of oesophageal adenocarcinoma cell line MFD-1

Project description:The open chromatin of new esophageal adenocarcinoma cell line MFD-1 has been profiled by ATAC-seq.

2018-04-06 | E-MTAB-6720 | biostudies-arrayexpress

ATAC-sequencing mice small intestinal epithelium with intestinal epithelium specific LSD1 knock out compared to wild type

Project description:To study the epigenetic regulation of intestinal epithelium we focus on the role of chromatin modulators. Lysine-specific histone demethylase 1a (KDM1A, LSD1) is one of the enzymes that can erase the H3K4me1/2 mark. To assess the role of LSD1 in intestinal epithelium we studied wild type (WT) (Villin-Cre -; Lsd1f/f) and intestinal-epithelial-specific knock-out (KO) (Villin-Cre+; Lsd1f/f) mice. We found that KO mice completely lack Paneth cells, and have altered stem cell characteristics compared to WT littermates. To assess genome-wide ATAC levels in WT and KO small intestines, we isolated intestinal epithelium tissue from wild type mice and LSD1 KO mice. This tissue was digested to single cells and performed ATAC seq as described in the protocols.

2021-03-23 | E-MTAB-8718 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data